Loreto Macia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Loreto Macia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aitor Gonzaga
Institute of Bioengineering, Miguel Hernández University, Elche, Spain; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
2 shared publications - Antonio Pérez-Martínez
Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain
2 shared publications - Bernat Soria
Institute of Bioengineering, Miguel Hernández University, Elche, Spain; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
2 shared publications - Carlos Solano
Hospital Clínico Universitario-INCLIVA, University of Valencia, Valencia, Spain
2 shared publications - Cristina Eguizabal
Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Advanced Therapies Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red Española de Terapias Avanzadas (TERAV and TERAV+), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Red de Inmunoterapia del Cáncer (REINCA), Madrid, Spain
2 shared publications - Eduardo Fernández
Bioengineering Institute, University Miguel Hernández, Elche, Spain
2 shared publications
Latest Publications
- Open Access
- 23 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1801
Non-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients
Objectives: COVID-19, caused by the SARS-CoV-2 virus, has infected over 777 million individuals and led to approximately 7 million deaths worldwide. Despite significant efforts to develop effective therapies, treatment remains largely supportive, especially for severe complications like acute respiratory distress syndrome (ARDS). Numerous compounds from diverse pharmacological classes are currently undergoing preclinical and clinical evaluation, targeting both the virus and the host immune response. Methods: Despite the large number of articles published and after a preliminary attempt was published, we discarded the option of a systematic review. Instead, we have done a description of therapies with these results and a tentative mechanism of action. Results: Preliminary studies and early-phase clinical trials have demonstrated the potential of Mesenchymal Stem Cells (MSCs) in mitigating severe lung damage in COVID-19 patients. Previous research has shown MSCs to be effective in treating various pulmonary conditions, including acute lung injury, idiopathic pulmonary fibrosis, ARDS, asthma, chronic obstructive pulmonary disease, and lung cancer. Their ability to reduce inflammation and promote tissue repair supports their potential role in managing COVID-19-related complications. This review demonstrates the utility of MSCs in the acute phase of COVID-19 and postulates the etiopathogenic role of mitochondria in Long-COVID. Even more, their combination with other therapies is also analyzed. Conclusions: While the therapeutic application of MSCs in COVID-19 is still in early stages, emerging evidence suggests promising outcomes. As research advances, MSCs may become an integral part of treatment strategies for severe COVID-19, particularly in addressing immune-related lung injury and promoting recovery. However, a full pathogenic mechanism may explain or unify the complexity of signs and symptoms of Long COVID and Post-Acute Sequelae (PASC).
- 23 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1801
Open AccessNon-Viral Therapy in COVID-19: Where Are We Standing? How Our Experience with COVID May Help Us Develop Cell Therapies for Long COVID Patients
Objectives: COVID-19, caused by the SARS-CoV-2 virus, has infected over 777 million individuals and led to approximately 7 million deaths worldwide. Despite significant efforts to develop effective therapies, treatment remains largely supportive, especially for severe complications like acute respiratory distress syndrome (ARDS). Numerous compounds from diverse pharmacological classes are currently undergoing preclinical and clinical evaluation, targeting both the virus and the host immune response. Methods: Despite the large number of articles published and after a preliminary attempt was published, we discarded the option of a systematic review. Instead, we have done a description of therapies with these results and a tentative mechanism of action. Results: Preliminary studies and early-phase clinical trials have demonstrated the potential of Mesenchymal Stem Cells (MSCs) in mitigating severe lung damage in COVID-19 patients. Previous research has shown MSCs to be effective in treating various pulmonary conditions, including acute lung injury, idiopathic pulmonary fibrosis, ARDS, asthma, chronic obstructive pulmonary disease, and lung cancer. Their ability to reduce inflammation and promote tissue repair supports their potential role in managing COVID-19-related complications. This review demonstrates the utility of MSCs in the acute phase of COVID-19 and postulates the etiopathogenic role of mitochondria in Long-COVID. Even more, their combination with other therapies is also analyzed. Conclusions: While the therapeutic application of MSCs in COVID-19 is still in early stages, emerging evidence suggests promising outcomes. As research advances, MSCs may become an integral part of treatment strategies for severe COVID-19, particularly in addressing immune-related lung injury and promoting recovery. However, a full pathogenic mechanism may explain or unify the complexity of signs and symptoms of Long COVID and Post-Acute Sequelae (PASC).
- Open Access
- 30 June 2025
- Published by MDPI AG in Preprints.org
Non-Viral Therapy in COVID-19: Where Are We Standing? Towards Cell Therapy Approaches for Long COVID Patients
Background: COVID-19, caused by the SARS-CoV-2 virus, has infected over 777 million individuals and led to approximately 7 million deaths worldwide. Despite significant efforts to develop effective therapies, treatment remains largely supportive, especially for severe complications like acute respiratory distress syndrome (ARDS). Numerous com-pounds from diverse pharmacological classes are currently undergoing preclinical and clinical evaluation, targeting both the virus and the host immune response. Methods: Despite the large number of articles published and after a preliminary attempt published, we discarded the option of a systematic review (PRISMA Method). Instead we have done a description of therapies with these results and tentative mechanism of action. Results: Preliminary studies and early-phase clinical trials have demonstrated the potential of Mesenchymal Stem Cells (MSCs) in mitigating severe lung damage in COVID-19 pa-tients. Previous research has shown MSCs to be effective in treating various pulmonary conditions, including acute lung injury, idiopathic pulmonary fibrosis, ARDS, asthma, chronic obstructive pulmonary disease, and lung cancer. Their ability to reduce inflam-mation and promote tissue repair supports their potential role in managing COVID-19-related complications. This review demonstrates the utility of MSCs on the acute phase of COVID-19 and postulates the etiopathogenic role of mitochondria in the Long-COVID. Even more, their combination with other therapies is also analyzed. Con-clusions: While the therapeutic application of MSCs in COVID-19 is still in early stages, emerging evidence suggests promising outcomes. As research advances, MSCs may be-come an integral part of treatment strategies for severe COVID-19, particularly in ad-dressing immune-related lung injury and promoting recovery. However, a full patho-genic mechanism which may explain or unify the complexity of signs and symptoms of Long COVID and Post-Acute Sequealae (PASC).
- 30 June 2025
- Published by MDPI AG in Preprints.org
Open AccessNon-Viral Therapy in COVID-19: Where Are We Standing? Towards Cell Therapy Approaches for Long COVID Patients
Background: COVID-19, caused by the SARS-CoV-2 virus, has infected over 777 million individuals and led to approximately 7 million deaths worldwide. Despite significant efforts to develop effective therapies, treatment remains largely supportive, especially for severe complications like acute respiratory distress syndrome (ARDS). Numerous com-pounds from diverse pharmacological classes are currently undergoing preclinical and clinical evaluation, targeting both the virus and the host immune response. Methods: Despite the large number of articles published and after a preliminary attempt published, we discarded the option of a systematic review (PRISMA Method). Instead we have done a description of therapies with these results and tentative mechanism of action. Results: Preliminary studies and early-phase clinical trials have demonstrated the potential of Mesenchymal Stem Cells (MSCs) in mitigating severe lung damage in COVID-19 pa-tients. Previous research has shown MSCs to be effective in treating various pulmonary conditions, including acute lung injury, idiopathic pulmonary fibrosis, ARDS, asthma, chronic obstructive pulmonary disease, and lung cancer. Their ability to reduce inflam-mation and promote tissue repair supports their potential role in managing COVID-19-related complications. This review demonstrates the utility of MSCs on the acute phase of COVID-19 and postulates the etiopathogenic role of mitochondria in the Long-COVID. Even more, their combination with other therapies is also analyzed. Con-clusions: While the therapeutic application of MSCs in COVID-19 is still in early stages, emerging evidence suggests promising outcomes. As research advances, MSCs may be-come an integral part of treatment strategies for severe COVID-19, particularly in ad-dressing immune-related lung injury and promoting recovery. However, a full patho-genic mechanism which may explain or unify the complexity of signs and symptoms of Long COVID and Post-Acute Sequealae (PASC).
- Open Access
- 1 January 2024
- Published by Universidad de Antioquia in Investigación y Educación en Enfermería
- Vol. 42 (2)
Temporally Prescription of Care: a Challenge to Advance in Nursing Sciences
- 1 January 2024
- Published by Universidad de Antioquia in Investigación y Educación en Enfermería
- Vol. 42 (2)
Open AccessTemporally Prescription of Care: a Challenge to Advance in Nursing Sciences